Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/13/2779524/0/en/Pliant-Therapeutics-Presentations-at-The-Liver-Meeting-2023-Highlight-Bexotegrast-an-Inhibitor-of-%CE%B1v%C3%9F6-and-%CE%B1v%C3%9F1-Integrins-in-Primary-Sclerosing-Cholangitis.html

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of preclinical data and clinical data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC). These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD). The meeting is being held November 10-14, 2023.

Read more at globenewswire.com

Related news for (PLRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.